David Shmuelov - Novolog Pharm Chief Company
| NVLG Stock | 169.90 0.50 0.30% |
Insider
David Shmuelov is Chief Company of Novolog Pharm Up 1966
| Age | 51 |
| Phone | 972 8 660 4400 |
| Web | https://www.novolog.co.il |
Novolog Pharm Management Efficiency
The company has return on total asset (ROA) of 0.0174 % which means that it generated a profit of $0.0174 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.106 %, meaning that it generated $0.106 on every $100 dollars invested by stockholders. Novolog Pharm's management efficiency ratios could be used to measure how well Novolog Pharm manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Rachel Mittelman | Azrieli Group | 45 | |
| Zvika Abramovich | Bezeq Israeli Telecommunication | N/A | |
| Nir Yehuda | Enlight Renewable Energy | 69 | |
| Michel Weiss | Tadiran Hldg | N/A | |
| Meron Carr | Enlight Renewable Energy | 50 | |
| Ronnie Kenneth | Nova | 62 | |
| Thomas Larson | Nova | N/A | |
| Daniel Vaknin | Tadiran Hldg | 57 | |
| Effi Aboody | Nova | 48 | |
| Nirit Zeevi | Azrieli Group | 44 | |
| Moran MamdorLeviad | Tadiran Hldg | 41 | |
| Shfi Bessen | Tadiran Hldg | 50 | |
| Amit Kurland | Bezeq Israeli Telecommunication | 52 | |
| Rafi Attias | Tadiran Hldg | 57 | |
| Elchanan Fridman | Tadiran Hldg | N/A | |
| Michael Avidan | Enlight Renewable Energy | N/A | |
| Eyal Henkin | Azrieli Group | 54 | |
| Ayelet Israeli | Enlight Renewable Energy | N/A | |
| Ilan Sigal | Bezeq Israeli Telecommunication | 48 | |
| Tobi Fischbein | Bezeq Israeli Telecommunication | 50 | |
| Ofer Yarom | Azrieli Group | N/A | |
Management Performance
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0174 |
Novolog Pharm Up Leadership Team
Elected by the shareholders, the Novolog Pharm's board of directors comprises two types of representatives: Novolog Pharm inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novolog. The board's role is to monitor Novolog Pharm's management team and ensure that shareholders' interests are well served. Novolog Pharm's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novolog Pharm's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Maoz Ramon, Chief Ltd | ||
| David Shmuelov, Chief Company | ||
| Rafi Friedman, CEO of a Subsidiary | ||
| Eran Taus, Chief Officer | ||
| Armin Shaun, Chief Ltd | ||
| Amir Shachar, Chief Officer | ||
| Amitai Gridish, Chief Ltd | ||
| Eli Dahan, Advisor CEO | ||
| Assaf Vardi, Vice President - Business Development, Sales & Marketing | ||
| Edity Streutman, VP System |
Novolog Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Novolog Pharm a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0174 | |||
| Profit Margin | 0.03 % | |||
| Operating Margin | 0.05 % | |||
| Current Valuation | 1.45 B | |||
| Shares Outstanding | 508.7 M | |||
| Shares Owned By Insiders | 42.45 % | |||
| Shares Owned By Institutions | 40.71 % | |||
| Price To Book | 3.24 X | |||
| Price To Sales | 0.99 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Novolog Stock
Novolog Pharm financial ratios help investors to determine whether Novolog Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Novolog with respect to the benefits of owning Novolog Pharm security.